Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

76.06 +1.26 (+1.68%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story
US durable goods orders surged in March, but with a mixed picture. Transportation equipment led the gain, while other sectors showed minimal growth or decline. 
Via Benzinga
Merck Reports Strong Q1 Earnings But Downgrades Full-Year Guidance: Retail Sentiment Brightens
Merck estimates that the impact of tariffs implemented to date will result in incremental costs of approximately $200 million. 
Via Stocktwits
Topics Government World Trade
Exposures Political Tariff
Merck’s (NYSE:MRK) Q1 Sales Beat Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue... 
Via StockStory
Topics Artificial Intelligence Earnings Intellectual Property
Exposures Artificial Intelligence Financial Intellectual Property
Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?
This is the third quarter of accelerating sales declines amid slow demand in China for Gardasil vaccines. 
Via Investor's Business Daily
Topics Earnings Government Stocks
Exposures Financial Political US Equities
Earnings Scheduled For April 24, 2025
Via Benzinga
Merck Announces First-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential. 
Via Benzinga
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug. 
Via Investor's Business Daily
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect. 
Via StockStory
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns. 
Via Benzinga
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved
Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence. 
Via Stocktwits
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Why Merck, Black Hills, And Virtus Investment Partners Are Winners For Passive Income
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Assessing Merck & Co: Insights From 9 Financial Analysts
Via Benzinga
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Price Over Earnings Overview: Merck & Co
Via Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology. 
Via Benzinga
Marjorie Taylor Greene Made Large Stock Purchases Ahead Of Trump's 90-Day Tariff Pause: Hakeem Jeffries Calls It 'Problematic'
Rep. Marjorie Taylor Greene (R-Ga.) disclosed her significant stock purchases made just before and on the day of former President Donald Trump's announcement to pause global tariffs. This announcement... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi, LLP
Via Business Wire
MRK Investors Have the Opportunity to Lead the Merck Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Deadline Soon: Merck & Co (MRK) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom
These robotics companies could find an opportunity if the latest round of tariffs stimulates an increase in U.S. manufacturing capacity. 
Via MarketBeat
Topics Government World Trade
Exposures Political Tariff
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.